Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FUTU NYSE:HHH NASDAQ:REG NASDAQ:TSHA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFUTUFutu$104.47-0.4%$142.11$80.50▼$202.53$14.63B0.522.59 million shs3.38 million shsHHHHoward Hughes$63.68-1.1%$63.87$61.01▼$91.07$3.80B1.15452,080 shs225,817 shsREGRegency Centers$77.50-1.3%$77.79$66.86▼$81.66$14.17B0.821.37 million shs696,153 shsTSHATaysha Gene Therapies$5.85-1.3%$5.49$2.25▼$7.30$1.67B1.252.68 million shs1.06 million shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFUTUFutu-4.82%-15.30%-32.36%-29.51%-2.60%HHHHoward Hughes+0.80%-0.17%+0.65%-10.99%-5.90%REGRegency Centers-0.54%+0.23%-2.23%-0.61%+9.63%TSHATaysha Gene Therapies+2.96%+6.86%-6.03%+30.68%+142.62%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFUTUFutu$104.47-0.4%$142.11$80.50▼$202.53$14.63B0.522.59 million shs3.38 million shsHHHHoward Hughes$63.68-1.1%$63.87$61.01▼$91.07$3.80B1.15452,080 shs225,817 shsREGRegency Centers$77.50-1.3%$77.79$66.86▼$81.66$14.17B0.821.37 million shs696,153 shsTSHATaysha Gene Therapies$5.85-1.3%$5.49$2.25▼$7.30$1.67B1.252.68 million shs1.06 million shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFUTUFutu-4.82%-15.30%-32.36%-29.51%-2.60%HHHHoward Hughes+0.80%-0.17%+0.65%-10.99%-5.90%REGRegency Centers-0.54%+0.23%-2.23%-0.61%+9.63%TSHATaysha Gene Therapies+2.96%+6.86%-6.03%+30.68%+142.62%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFUTUFutu 2.60Moderate Buy$162.8055.83% UpsideHHHHoward Hughes 1.33Sell$85.0033.47% UpsideREGRegency Centers 2.41Hold$82.075.91% UpsideTSHATaysha Gene Therapies 3.00Buy$11.6499.08% UpsideCurrent Analyst Ratings BreakdownLatest HHH, TSHA, FUTU, and REG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2026REGRegency Centers Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$85.005/28/2026FUTUFutu Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$170.505/26/2026REGRegency Centers Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$85.00 ➝ $88.005/25/2026FUTUFutu The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$102.135/22/2026FUTUFutu JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral$300.00 ➝ $87.005/18/2026REGRegency Centers UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$75.00 ➝ $81.005/12/2026REGRegency Centers BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$85.00 ➝ $90.005/11/2026REGRegency Centers BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/8/2026FUTUFutu Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/5/2026REGRegency Centers CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$76.00 ➝ $82.005/4/2026FUTUFutu The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$205.00(Data available from 5/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFUTUFutu$2.94B4.99$9.91 per share10.54$36.96 per share2.83HHHHoward Hughes$1.47B2.57$6.18 per share10.30$49.41 per share1.29REGRegency Centers$1.55B9.13$4.96 per share15.61$37.90 per share2.04TSHATaysha Gene Therapies$9.77M171.92N/AN/A$0.74 per share7.90Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFUTUFutu$1.46B$10.2810.158.110.8249.63%32.24%5.33%N/AHHHHoward Hughes$131.88M$2.0431.2118.68N/A8.04%5.41%1.61%N/AREGRegency Centers$527.46M$2.9026.6815.253.3534.47%7.99%4.22%7/29/2026 (Estimated)TSHATaysha Gene Therapies-$109M-$0.38N/AN/AN/AN/A-56.07%-40.16%8/11/2026 (Estimated)Latest HHH, TSHA, FUTU, and REG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/28/2026Q1 2026FUTUFutu$2.89$0.77-$2.12$0.77$761.35 million$694.17 million5/7/2026Q1 2026HHHHoward Hughes$0.08$0.14+$0.06$0.14N/A$235.92 million5/6/2026Q1 2026TSHATaysha Gene Therapies-$0.10-$0.12-$0.02-$0.12$0.76 millionN/A3/19/2026Q4 2025TSHATaysha Gene Therapies-$0.11-$0.08+$0.03-$0.08$1.89 million$5.49 million3/12/2026Q4 2025FUTUFutu$3.06$3.07+$0.01$3.07$788.73 million$827.15 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthFUTUFutu$2.552.44%N/A24.81%N/AHHHHoward HughesN/AN/AN/AN/AN/AREGRegency Centers$3.023.90%+3.82%104.14%5 YearsTSHATaysha Gene TherapiesN/AN/AN/AN/AN/ALatest HHH, TSHA, FUTU, and REG DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/6/2026REGRegency Centersquarterly$0.75503.88%6/12/20266/12/20267/2/20264/2/2026FUTUFutuspecial$2.604/16/20264/16/20264/29/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFUTUFutuN/A1.191.19HHHHoward Hughes1.971.581.58REGRegency Centers0.722.142.14TSHATaysha Gene Therapies0.2314.0414.04Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFUTUFutuN/AHHHHoward Hughes93.83%REGRegency Centers96.07%TSHATaysha Gene Therapies77.70%Insider OwnershipCompanyInsider OwnershipFUTUFutu35.20%HHHHoward Hughes48.00%REGRegency Centers1.00%TSHATaysha Gene Therapies3.78%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFUTUFutu3,540140.17 million90.83 millionOptionableHHHHoward Hughes60859.62 million31.01 millionOptionableREGRegency Centers440183.10 million181.27 millionOptionableTSHATaysha Gene Therapies180287.36 million276.50 millionOptionableHHH, TSHA, FUTU, and REG HeadlinesRecent News About These CompaniesASPIRE Rett Syndrome Trial Puts Taysha’s TSHA-102 Gene Therapy in Focus for InvestorsMay 22, 2026 | tipranks.comNeedham ups Taysha target on ‘derisking’ TSHA-102 newsMay 15, 2026 | msn.comTaysha Gene Therapies (TSHA) Reports Financial Results for Q1 2026May 14, 2026 | finance.yahoo.comCanaccord Keeps Buy Rating on Taysha (TSHA) After Q1 HighlightsMay 11, 2026 | insidermonkey.comTaysha Gene Therapies Ramps Up Ahead of TSHA-102 BLAMay 10, 2026 | tipranks.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Average Recommendation of "Buy" by BrokeragesMay 10, 2026 | marketbeat.comAssessing Taysha Gene Therapies (TSHA) Valuation After Strong Momentum And Recent VolatilityMay 9, 2026 | finance.yahoo.comTaysha Gene Therapies, Inc. Q1 2026 Earnings Call SummaryMay 9, 2026 | finance.yahoo.comTaysha Gene Therapies (NASDAQ:TSHA) Lowered to "Sell" Rating by Wall Street ZenMay 9, 2026 | marketbeat.comTaysha outlines PPQ completion by Q4 2026 while targeting a TSHA-102 BLA option based on a 6-month interim analysisMay 7, 2026 | seekingalpha.comTaysha Gene Therapies Q1 Earnings Call HighlightsMay 7, 2026 | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Issues Earnings ResultsMay 6, 2026 | marketbeat.comTaysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 6, 2026 | globenewswire.comTaysha Gene Therapies (NASDAQ:TSHA) Hits New 12-Month High - Here's What HappenedMay 5, 2026 | marketbeat.comTaysha Gene Therapies (TSHA) to Release Earnings on WednesdayMay 2, 2026 | marketbeat.comTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 1, 2026 | globenewswire.comTaysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6April 29, 2026 | globenewswire.comHas Taysha Gene Therapies (TSHA) Run Too Far After A 259% One Year Surge?April 28, 2026 | finance.yahoo.comTaysha Gene Therapies Reports Preclinical Data Supporting TSHA-102 Gene Therapy for Rett Syndrome at ASGCT Annual MeetingApril 27, 2026 | quiverquant.comQTaysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual MeetingApril 27, 2026 | globenewswire.comTaysha Gene Therapies, Inc. ($TSHA) CEO and Director 2025 Pay RevealedApril 22, 2026 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesViking Sails to All-Time Highs—Fundamentals Signal More to ComeBy Chris Markoch | May 15, 2026Palantir and Dell Build an AI OS for the ParanoidBy Chris Markoch | May 24, 2026Water Infrastructure: Why This Boring Sector Could Get ExcitingBy Chris Markoch | May 9, 20262 ETFs to Play Both Sides of the Iran War CeasefireBy Nathan Reiff | May 4, 2026NerdWallet’s Growth Story Looks Strong—But Can It Last?By Peter Frank | April 30, 2026HHH, TSHA, FUTU, and REG Company DescriptionsFutu NASDAQ:FUTU$104.47 -0.44 (-0.42%) As of 03:21 PM Eastern This is a fair market value price provided by Massive. Learn more.Futu Holdings Limited provides digitalized securities brokerage and wealth management product distribution service in Hong Kong and internationally. It offers online financial services, including securities and derivative trades brokerage, margin financing and fund distribution services through its Futubull and Moomoo digital platforms. The company also provides financial information and online community services; online wealth management services under the Money Plus brand name through its Futubull and moomoo platforms, which provides its client access to mutual funds, private funds, bonds, structured products, and other wealth management products; market data and information services; and NiuNiu Community, which serves as an open forum for users and clients to share insights, ask questions, and exchange ideas. Futu Holdings Limited was founded in 2007 and is headquartered in Sheung Wan, Hong Kong.Howard Hughes NYSE:HHH$63.68 -0.70 (-1.08%) As of 03:20 PM Eastern This is a fair market value price provided by Massive. Learn more.Howard Hughes Holdings Inc., together with its subsidiaries, operates as a real estate development company in the United States. It operates in four segments: Operating Assets; Master Planned Communities (MPCs); Seaport; and Strategic Developments. The Operating Assets segment consists of developed or acquired retail, office, and multi-family properties along with other retail investments. Its MPCs segment develops, sells, and leases residential and commercial land designated for long-term community development projects in and around Las Vegas, Nevada; Houston, Texas; and Phoenix, Arizona. The Seaport segment is involved in the landlord operations, managed businesses, and events and sponsorships services of its restaurant, retail, and entertain properties in Pier 17, New York City; Historic Area/Uplands; and Tin Building, as well as in 250 Water Street and in the Jean-Georges restaurants. The Strategic Development segment develops and redevelops residential condominiums and commercial properties. It serves homebuilders. Howard Hughes Holdings Inc. was founded in 2010 and is headquartered in The Woodlands, Texas.Regency Centers NASDAQ:REG$77.50 -1.03 (-1.31%) As of 03:21 PM Eastern This is a fair market value price provided by Massive. Learn more.Regency Centers is a preeminent national owner, operator, and developer of shopping centers located in suburban trade areas with compelling demographics. Our portfolio includes thriving properties merchandised with highly productive grocers, restaurants, service providers, and best-in-class retailers that connect to their neighborhoods, communities, and customers. Operating as a fully integrated real estate company, Regency Centers is a qualified real estate investment trust (REIT) that is self-administered, self-managed, and an S&P 500 Index member.Taysha Gene Therapies NASDAQ:TSHA$5.84 -0.08 (-1.27%) As of 03:21 PM Eastern This is a fair market value price provided by Massive. Learn more.Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys Dollar Tree Keeps Winning After Family Dollar Divorce Salesforce Stock Finds Support as AI Momentum Builds Marvell’s Pullback May Be the Setup Bulls Were Waiting For Snowflake and the Snowballing Impact of its AI Flywheel China Deal Ignites Boeing's Financial Afterburners IREN Is Flipping the Switch from Bitcoin to AI Flight Path to Profits: American Airlines Bets on SpaceX Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
